[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100476526":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":28,"responsibleParty":46,"collaborators":48,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":10,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Singlera Genomics Inc.","INDUSTRY",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Positive group",null,"All the subjects who completed colorectal cancer polygene methylation test at baseline completed colonoscopy within 3 months. Colorectal cancer diagnosed by colonoscopy, adenoma or polyp lesions found after treatment will reach the end of the study. The tumor history of family members was tracked for patients who met the end point of the study. The positive subjects who did not reach the end point of the study underwent three center visits at 12, 36 and 60 months after enrollment respectively, including history taking, colonoscopy, FIT test and blood CEA test. Another telephone follow-up was conducted at 24 and 48 months, respectively.",{"label":13,"type":10,"description":14,"interventionNames":10},"Negative group","The subjects who completed colorectal cancer polygene methylation test at baseline, and those with negative test results (n= 500, direct extraction method) completed colonoscopy within 3 months. The end points and follow-up were the same as those in the positive group. The negative group was compared with the positive group to observe the difference of negative predictive value and survival outcome.",[16],{"name":17,"affiliation":5,"role":18},"Rui Liu, Doctor","PRINCIPAL_INVESTIGATOR",[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Jin Gu, Doctor","CONTACT","010-57830127","yuanping_632@163.com",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":10},"Ping Yuan","15210919487",[29],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Peking University Shougang Hospital","RECRUITING","Beijing","Beijing Municipality","100144","China","CN",{"type":38,"coordinates":39},"Point",[40,41],116.39723,39.9075,{"lat":41,"lon":40},[44,45],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"name":26,"role":22,"phone":27,"phoneExt":10,"email":10},{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[49],{"name":30,"class":50},"OTHER","100476526","a-prospective-cohort-study-on-colorectal-cancer-screening-in-community-population-100476526",false,"NCT05485077","A Prospective Cohort Study on Colorectal Cancer Screening in Community Population","Colorectal Cancer Screening Cohort Study in Shougang Community Population Based on Polygene Methylation Detection Technology","Inclusion Criteria:\n\n1. Chronological age ≥40 years;\n2. Full capacity for action;\n3. After enrollment, the participants were able to complete the Colorectal Cancer Risk Factor Assessment Questionnaire and the annual follow-up interviews;\n4. In the course of the study, the information related to tumor diagnosis in other hospitals can be timely fed back to the researchers;\n\nExclusion Criteria:\n\n1. History of colorectal cancer and other malignant tumors;\n2. Previous colorectal resection;\n3. undergoing any cancer-related treatment;\n4. Patients who have received major surgical treatment such as blood transfusion or transplantation within 3 months;\n5. Participate in other interventional clinical investigators within 3 months;\n6. Pregnant or lactating women;\n7. Have autoimmune disease, hereditary disease, mental illness\u002Fdisability, etc\n8. Poor compliance, unable to complete the study.",true,"ALL","40 Years",{"count":62,"type":63},18000,"ESTIMATED","OBSERVATIONAL","This study will validate the real world results of polygene methylation detection in colorectal cancer in a large prospective community cohort. In this study, questionnaire survey and polygene methylation detection technology of colorectal cancer were used as preliminary screening methods, and colonoscopy was used as further validation examination method to screen colorectal cancer and precancerous lesions. The diagnosis and outcome of all lesions were based on colonoscopy and pathological examination.",[67],"Colorectal Cancer",[69,70],"ctDNA methylation","Community population screening","2024-04-15",{"date":73,"type":74},"2024-04-17","ACTUAL",{"date":76,"type":74},"2022-07-09",{"date":78,"type":63},"2028-07-09",{"name":5,"class":6},1]